<br>        Inclusion Criteria:<br><br>          -  Patient is ineligible for treatment with IV tPA according to licensing criteria (e.g.<br><br>        anticoagulation, previous surgery, or beyond 4.5 hours after symptom onset).<br><br>          -  Randomization within 7 hours after stroke onset.<br><br>          -  Endovascular treatment is expected to be finished within 8 hours after symptom onset<br>             by judgment of the interventional Neuroradiologist in charge.<br><br>          -  Patient must demonstrate clinical signs and symptoms attributable to target area of<br>             occlusion consistent with the diagnosis of ischemic stroke, including impairment of<br>             the following: language, motor function, sensation, cognition, gaze, and/or vision for<br>             at least 30 minutes without relevant improvement.<br><br>          -  Female and male patient between 18-80 years of age<br><br>          -  NIHSS Score of >7 and <25<br><br>          -  Patient signed informed consent (IC) form by patient, legal representative, or by an<br>             independent physician who is familiar with this types of illness if the other options<br>             are not possible.<br><br>          -  A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the<br>             thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or<br>             the intracranial segment of the distal internal carotid artery (ICA).<br><br>          -  Prior to new focal neurological deficit, mRS score was =1.<br><br>        Exclusion Criteria:<br><br>          -  Patient is eligible for and receives IV tPA according to licensing criteria<br><br>          -  Patient with an international normalized ratio (INR) of >3<br><br>          -  Patient is an active participant in another drug or device treatment trial for any<br>             disease state, or patient is expected to start participation in another drug or device<br>             treatment trial while enrolled in this protocol, unless approved by Sponsor.<br><br>          -  Patient has pre-existing neurological or psychiatric disease that could impede the<br>             study results or would confound the neurological or functional evaluations.<br><br>          -  Patient has carotid dissection, high grade stenosis = 70% proximal to occlusion that<br>             requires stenting, or excessive tortuosity to gain access to occlusion, as determined<br>             by MRA/ CTA of neck and head.<br><br>          -  Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection<br>             or aneurysm, no arterial transfemoral access)<br><br>          -  Patient has history of contraindication for contrast medium.<br><br>          -  Patient is known to have infective endocarditis<br><br>          -  CT scan or MRI with evidence of: Mass effect or intracranial tumor, or hypodensity on<br>             unenhanced CT and cerebral blood volume (CBV) drop on CBV maps on Computed Tomography<br>             Perfusion (CTP), or, alternatively as per institutional standard, restricted diffusion<br>             on Diffusion weighted imaging (DWI) with an Alberta Stroke Program Early CT score<br>             (ASPECTs) of 6 or less<br><br>          -  Female of childbearing potential who is known to be pregnant and/or lactating or who<br>             has a positive pregnancy test on admission.<br><br>          -  Patients anticipated life expectancy is less than 6 Months.<br>